Inclusion Criteria:

- Diagnosis of extracranial Ewing sarcoma or peripheral primitive neuroectodermal tumor
of bone or soft tissue:

- Newly diagnosed disease

- Disease confirmed by biopsy only with no attempt at complete or partial
resection

- Unplanned excision allowed provided adequate imaging was obtained prior to
surgery and incompletely resected disease is controlled by local therapy

- No esthesioneuroblastoma

- Localized disease, including any of the following sites:

- Chest wall tumors with ipsilateral pleural effusions, ipsilateral positive
pleural fluid cytology, or ipsilateral pleural based secondary tumor nodules;

- No contralateral pleural effusions or pleural nodules

- Regional lymph nodes that are clinically suspicious or confirmed by biopsy

- No distant lymph node metastases

- Extra-dural tumors arising in the bony skull

- No tumors arising in the intra-dural soft tissue or the intra-dural region
of the spine

- No evidence of metastatic disease, defined as any of the following:

- Lesions that are discontinuous from the primary tumor

- Lesions that are not regional lymph nodes

- Lesions that do not share a body cavity with the primary tumor

- No evidence by CT scan of metastatic lung disease, defined as any of the following:

- One pulmonary nodule > 1 cm in diameter or more than one nodule > 0.5 cm
diameter

- Pulmonary nodules that are resected and are not found to be metastatic
Ewing sarcoma are allowed

- Biopsy proven solitary nodules measuring 0.5 to 1.0 cm or multiple nodules
measuring 0.3 to 0.5 cm

- Solitary nodules measuring < 0.5 cm or multiple nodules measuring < 0.3 cm
are allowed unless biopsy proven to be metastatic (biopsy is not required)

- Karnofsky performance status (PS) 0-2 (>= 16 years old) OR Lansky PS 0-2 (< 16 years
old)

- Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR serum
creatinine based on age/gender as follows:

- 1 month to < 6 months old (males and females 0.4 mg/dL)

- 6 months to < 1 year old (males and females 0.5 mg/dL)

- 1 to < 2 years old (males and females 0.6 mg/dL)

- 2 to < 6 years old (males and females 0.8 mg/dL)

- 6 to < 10 years old (males and females 1.0 mg/dL)

- 10 to < 13 years old (males and females 1.2 mg/dL)

- 13 to < 16 years old (males 1.5 mg/dL and females 1.4 mg/dL)

- >= 16 years old (males 1.7 mg/dL and females 1.4 mg/dL)

- AST or ALT < 2.5 times ULN for age

- Total bilirubin =< 1.5 times upper limit of normal (ULN) for age

- Shortening fraction of >= 27% by ECHO or ejection fraction of >= 50% by radionuclide
angiogram (MUGA)

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No prior chemotherapy or radiotherapy

- No concurrent pegfilgrastim (Neulasta) or sargramostim (GM-CSF)

- No other concurrent cancer chemotherapy or immunomodulating agents, including
steroids, unless used as an antiemetic